Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Neoplasms × Vorinostat × Clear all

Phase

Status

Completed 5 Terminated 2 Unknown 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroblastoma 2 Wilms Tumor 1 Thrombocythemia, Essential 1 Sarcoma, Ewing 1 Rhabdomyosarcoma 1 Recurrence 1 Polycythemia Vera 1 Polycythemia 1 Ovarian Neoplasms 1 Neuroectodermal Tumors 1 Neoplasms, Plasma Cell 1 Neoplasms, Germ Cell and Embryonal 1 Neoplasms 1 Mycosis Fungoides 1 Multiple Myeloma 1 Lymphoma, T-Cell, Cutaneous 1 Leukemia, Myeloid, Acute 1 Hepatoblastoma 1 Hematologic Diseases 1 Breast Neoplasms 1

Interventions

Drug Therapy 16 Exercise 15 Capecitabine 11 Blood Specimen Collection 11 Surveys and Questionnaires 9 Radiotherapy 9 pembrolizumab 8 Paclitaxel 8 Dexamethasone 8 Standard of Care 7 Oxaliplatin 7 Nivolumab 6 Interviews as Topic 6 Fluorouracil 6 Cisplatin 6 Biopsy 6 apatinib 5 Neoadjuvant Therapy 5 Mindfulness-Based Cognitive Therapy 5 Metformin 5 Gemcitabine 5 Cyclophosphamide 5 atezolizumab 4 Therapeutics 4 Rivaroxaban 4 Radiosurgery 4 Positron Emission Tomography Computed Tomography 4 Nutritional Status 4 Methylprednisolone 4 Ipilimumab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03561259 2023-02-16

OPTIMUM

Jubilant DraxImage Inc.

Phase 2 Unknown

Neoplasms, Neuroblastoma, Neuroectodermal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡